North America Is Expected To Dominate The Global Bio-Engineered Stent Market And This Is Attributed To The High Presence Of The Geriatric Population
The growing prevalence of cardiovascular diseases such as ischemic heart disease and coronary heart disease is significantly fueling the growth of the bio-engineered stent market. According to the U.S. National Library of Medicine, IHD (ischemic heart disease) affects around 126 million individuals (1,655 per 100,000), which is approximately 1.72% of the world’s population. Nine million deaths were caused by IHD globally. According to the National Center for Chronic Disease Prevention and Health Promotion, about 655,000 Americans die from heart disease each year—that’s 1 in every 4 deaths. Bio-engineered stents are used to expand the blood vessel to prevent a blockage of arteries.
In September 2020, OrbusNeich Medical Co. Ltd. has announced that the National Medical Products Administration (NMPA) has granted market approval for the COMBO BIO-ENGINEERED SIROLIMUS ELUTING STENT in China.
In May 2017, Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx Drug-Eluting Stent (DES). The Resolute Onyx DES builds on the proven clinical performance and superior deliverability of the Resolute Integrity DES to further strengthen the gold standard safety and efficacy of DES technology.
North America is expected to dominate the global bio-engineered stent market and this is attributed to the high presence of the geriatric population which is increasing the prevalence of chronic diseases such as cardiovascular disease. According to the U.S. Census Bureau, there were 40.3 million U.S. residents 65 years and older in the 2010 Census and more than 54 million on July 1, 2019.
Bio-engineered Stent, as its name suggests is a bio-engineered stem cell implantation technology that aids in the accelerated normal healing of a damaged or blocked vessel wall after successful arterial opening. The procedure has the potential to reduce or eliminate the need for aortic valve replacement. Bio-engineered Stent is used in the treatment of patients with severe congenital heart defects. The use of these stents in such patients decreases the risks of suffering a heart attack or stroke significantly, which further improves the patient's quality of life. Bio-engineered Stent is made from specially formulated cells taken from human umbilical cord blood. These cells have the ability to generate their own collagen (skin's biggest organ) and epithelial (lining of the internal organs like the lungs and the gastrointestinal tract) proteins needed for normal growth and repair of the aorta. After successful implantation, the cells replicate themselves and replicate within the damaged area, thus repairing the aortic wall.
Comments
Post a Comment